MOYOM Drives European Regenerative Aesthetics with APHRANEL® Certification and Strategic Collaboration

MOYOM Advances the European Regenerative Aesthetics Scene

In a significant stride toward enhancing regenerative aesthetics in Europe, MOYOM, the innovative biotechnology firm behind the APHRANEL® line of products, has recently achieved two pivotal milestones. On July 7, 2026, the company obtained the much-coveted EU Medical Device Regulation (MDR) certification for its flagship product, APHRANEL®. This certification was conferred by BSI UK, one of the world’s most respected notified bodies, and is a testament to APHRANEL®’s adherence to the highest standards of quality, safety, and clinical performance as mandated by European regulations.

This accomplishment not only paves the way for MOYOM to penetrate the expansive European market but also signals a new phase in the company’s international growth trajectory. Importantly, MOYOM acknowledges that achieving regulatory approval is not an endpoint but rather the beginning of a broader scientific narrative. "Gaining market access is just the first hurdle; earning the trust of medical professionals is paramount," the company stated.

To bolster this commitment to trust and scientific integrity, MOYOM has announced a strategic collaboration with Dr. Patrick Trévidic and Expert2Expert (E2E), an independent scientific partner with over 20 years of experience supporting leading practitioners in aesthetic medicine. This partnership aims to cultivate a long-term platform for regenerative aesthetics throughout Europe, which will include extensive anatomical research, advanced cadaver studies, the generation of clinical evidence, and medical training programs.

Dr. Trévidic, an esteemed aesthetic surgeon with 35 years of experience, will lead this initiative. His credentials include numerous clinical studies, international teaching engagements, and over 75 peer-reviewed publications. Through this alliance, both parties are focused on developing scientific programs centered on advanced anatomy studies, European clinical research, medical education initiatives, and scientific collaboration that will fortify the medical credibility of APHRANEL® across Europe.

Patrice Delobel, the European Chief Medical and Marketing Officer at MOYOM, shared his vision for the partnership: "When I joined MOYOM, my ambition extended beyond merely overseeing the European launch of APHRANEL®. I aspired to help establish a scientific platform upon which doctors could rely for years to come. Teaming up with Expert2Expert, led by Dr. Trévidic, marks one of the first and most significant steps toward realizing that vision."

Dr. Trévidic echoed this sentiment, stating, "Scientific progress never stems from a single entity; it’s fostered through collaboration, curiosity, and an unwavering pursuit of solid evidence. I am thrilled that Expert2Expert has the opportunity to work alongside MOYOM in this venture, laying the scientific groundwork for the future of regenerative aesthetic medicine in Europe."

These achievements represent the foundation of MOYOM's enduring scientific commitment. The company espouses a philosophy centered around patient care throughout life, where rigorous science, safe practices, and meaningful education intertwine. This ethos prioritizes long-term trust-building with medical professionals through continuous learning, collaboration, and evidence generation.

Ultimately, guided by the overarching value of lifelong healthcare, MOYOM remains dedicated to scientific research, medical education, and evidence generation to shape the future of regenerative aesthetics. Innovation may begin in the laboratory, but it is scientific evidence that transforms clinical practice, and trust is what shapes the future.

With their strategic initiatives and the strong partnership with Expert2Expert, MOYOM sets the stage for a transformative impact in the aesthetic market, ushering in a new era of trusted and effective regenerative solutions for medical professionals and patients alike.